Capital New York
June 4, 2015
Feinstein Institute, Ohio firm Team to Create Neural Tourniquet
By Dan Goldberg
The Feinstein Institute for Medical Research, the research arm of North Shore-LIJ, will announce a deal Thursday morning with Batelle, an Ohio research and development company, to create a neural tourniquet.
The device will work by sending a neural signal to prime the platelets in the body responsible for coagulation. That will allow the body to clot 50 percent faster, said Dr. Chris Czura, the co-inventor.
The product is still several years away from being commercially viable and must first be designed and developed and then receive approval from the federal Food and Drug Administration.
Czura said he envisions it being applicable on the battlefield, for trauma patients and for the 50 million planned surgeries that take place in the United States each year.
"This would be the first time something would be brought to the surgeon's arsenal of tools to prepare a patient's body prior to the bleeding event," he said.
Whether or not the device gets to market, the partnership is indicative of LIJ's strategy for Feinstein, which envisions capitalizing on growing markets to increase revenue.
Crain's Health Pulse
June 4, 2015
Feinstein Pens Deal to Commercialize Technology
The Feinstein Institute for Medical Research, the Manhasset, L.I., research arm of the North Shore-LIJ Health System, is partnering with Battelle to develop and commercialize one of Feinstein's promising inventions. The partnership, announced today, aims to bring to market a neural tourniquet treatment that slows bleeding by stimulating the vagus nerve.
The neural tourniquet is based on intellectual property developed over 15 years by Feinstein's Drs. Kevin Tracey, Christopher Czura and Jared Huston, with initial support provided by the Defense Advanced Research Projects Agency.
Battelle, a nonprofit research and development company based in Columbus, Ohio, will focus on device design, development and prototyping. The prototype developed by Battelle will be licensed to a device production and commercialization company for mass production.
The Feinstein technology uses electronic nerve stimulation to slow blood loss. The neural tourniquet's projected applications are in surgeries, emergency medicine and on the battlefield. The estimated time to market is three to five years.
According to Feinstein, bioelectronic medicine focuses on the use of a device to stimulate a specific nerve to send a signal to the body to treat a problem. Feinstein's research with nerve stimulation showed that the device can significantly reduce bleeding. A 60-second electrical stimulation of neural pathways to the spleen tells the body to prepare for clotting in the event of a wound. The primed coagulation system is able to clot 50% faster and halve blood loss, according to Feinstein.
A year ago, NS-LIJ announced an agreement with i360medical Ltd., a Dublin company that specializes in developing medical devices and bringing them to the global market. Feinstein worked with the Irish firm on market research and validation to produce a study on the market viability of the neural tourniquet that helped seal the deal with Battelle. Researchers pictured the device being used by surgical teams to reduce blood loss in operating room, by first-responders who can apply the device to trauma victims at accidents, and by soldiers heading into battle to proactively curb blood loss in the event they are wounded.